TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a “Buy”
On December 18, 2025, The Fly reported that TD Cowen initiated coverage of RAPT Therapeutics, Inc.
Rapt Therapeutics Inc. (RAPT)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 0 | $0 | 0% | |
| 2. | Siren L.L.C. Raymond Debbane | 0 | $0 | 0% | |
| 3. | Soleus Capital Guy Levy | 0 | $0 | 0% | |
| 4. | Atika Capital Brad Farber | 0 | $0 | 0% | |
| 5. | Hudson Bay Capital Management Sander Gerber | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.05 | 2,500 | $50,125.00 | 6,500 | 2023-03-14 | Filing | |
| $19.95 | 600 | $11,970.00 | 14,900 | 2023-03-14 | Filing | |
| $18.48 | 400 | $7,392.00 | 14,300 | 2023-03-14 | Filing | |
| $18.75 | 1,500 | $28,125.00 | 13,900 | 2023-03-14 | Filing | |
| $12.45 | 63 | $784.66 | 42,189 | 2022-05-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.78 | 898 | $20,456.44 | 27,820 | 2024-01-05 | Filing | |
| $21.68 | 2,500 | $54,200.00 | 15,020 | 2023-12-21 | Filing | |
| $13.72 | 1,500 | $20,580.00 | 17,520 | 2023-11-28 | Filing | |
| $15.77 | 2,500 | $39,425.00 | 18,789 | 2023-10-03 | Filing | |
| $18.92 | 2,500 | $47,300.00 | 21,289 | 2023-08-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Wells Fargo Boosts RAPT Therapeutics (RAPT) PT to $48 on Promising Anti-IgE Drug Data
RAPT Therapeutics Inc. (NASDAQ:RAPT) is one of the hot stocks to buy with huge upside potential.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
10 Best Growth Stocks for 2022
The optimism surrounding the global economic recovery has been dented by supply chain concerns and rising inflation.
Yale University Stock Portfolio: Top 10 Picks
Yale University is one of the richest academic institutions across the world, boasting an endowment value of more than $42 billion at the end of June 2021, up from $31 billion at the end of the second...
5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital.
Hedge Fund Resource Center